In Vitro Efficient Expansion of Tumor Cells Deriving from Different Types of Human Tumor Samples

Medical Sciences

Ilaria Turin³  Roberta Schiavo⁴  Marcello Maestri⁶  Ombretta Luinetti²  Barbara Dal Bello²  Marco Paulli²  Paolo Dionigi⁶  Marianna Roccio⁵  Arsenio Spinillo¹  Federica Ferulli³  Matteo Tanzi³  Rita Maccario⁷  Daniela Montagna³ 

[1] Dipartimento di Scienze Clinico-chirurgiche, Pediatriche e Diagnostiche, Università di Pavia, Pavia 20100, Italy; E-Mail:;U.C. Anatomia Patologica, Fondazione IRCCS Policlinico S. Matteo, Pavia 27100, Italy; E-Mails:;Laboratorio di Immunologia dei Trapianti, Oncoematologia Pediatrica, Fondazione IRCCS Policlinico S. Matteo, Pavia 27100, Italy; E-Mails:;U.O. Microbiologia, Ospedale Guglielmo Da Saliceto, Piacenza 29100, Italy; E-Mail:;S.C. Ostetricia e Ginecologia, Fondazione IRCCS Policlinico S. Matteo 27100, Pavia; E-Mail:;Chirurgia Generale I Fondazione IRCCS Policlinico S. Matteo, Pavia 27100, Italy; E-Mails:;Cell Factory, Lab. Ricerca, Fondazione IRCCS Policlinico S. Matteo, Pavia 27100, Italy; E-Mail:

关键词: tumor cell line;    in vitro model;    cell culture;    immunomagnetic selection;   

DOI  :  10.3390/medsci2020070

来源: mdpi

【 摘 要 】

Obtaining human tumor cell lines from fresh tumors is essential to advance our understanding of antitumor immune surveillance mechanisms and to develop new ex vivo strategies to generate an efficient anti-tumor response. The present study delineates a simple and rapid method for efficiently establishing primary cultures starting from tumor samples of different types, while maintaining the immuno-histochemical characteristics of the original tumor. We compared two different strategies to disaggregate tumor specimens. After short or long term in vitro expansion, cells analyzed for the presence of malignant cells demonstrated their neoplastic origin. Considering that tumor cells may be isolated in a closed system with high efficiency, we propose this methodology for the ex vivo expansion of tumor cells to be used to evaluate suitable new drugs or to generate tumor-specific cytotoxic T lymphocytes or vaccines.

【 授权许可】

CC BY   
© 2014 by the authors; licensee MDPI, Basel, Switzerland.